Cytogenetic Analysis of HER Receptors in Breast Cancer Patients
Author Information
Author(s): Andrea Sassen, Justine Rochon, Peter Wild, Arndt Hartmann, Ferdinand Hofstaedter, Stephan Schwarz, Gero Brockhoff
Primary Institution: Institute of Pathology, University of Regensburg
Hypothesis
Does the amplification of HER1, HER2, HER3, and HER4 genes correlate with breast cancer outcomes?
Conclusion
The study suggests that analyzing HER3 and HER4 gene amplification can provide additional prognostic information for breast cancer patients.
Supporting Evidence
- HER3 gene amplification negatively impacts disease-free survival.
- HER4 amplification shows a positive trend in overall and disease-free survival.
- The study used a large sample size of 278 breast cancer patients.
Takeaway
This study looked at how certain genes related to breast cancer might help doctors understand how to treat patients better.
Methodology
Fluorescence in situ hybridization (FISH) and immunohistochemistry were used to analyze HER1 to HER4 in tissue samples from breast cancer patients.
Potential Biases
Potential biases in sample selection and analysis methods.
Limitations
The study is retrospective and may not account for all variables affecting patient outcomes.
Participant Demographics
278 female patients with invasive lobular or ductal unilateral primary breast cancer, median age 55 years.
Statistical Information
P-Value
0.031
Confidence Interval
95% CI 1.08 to 5.11
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website